Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | PTPRB | P23467 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3752221 | 0.91 | ALDH1A1 (0.38) | ALDH1A1MGAMGAASIMGAM2 | |
| SCHEMBL18947201 | 0.87 | ALDH1A1 (0.35) | ALDH1A1MGAMGAASIMGAM2 | |
| SCHEMBL15961396 | 0.82 | ALDH1A1 (0.36) | ALDH1A1MGAMGAASIMGAM2 | |
| SCHEMBL11652293 | 0.82 | SMN1; SMN2 (0.46) | ALDH1A1MGAMGAASIMGAM2 | |
| SCHEMBL8686256 | 0.81 | TSHR (0.55) | ALDH1A1MGAMGAASIMGAM2 | |
| SCHEMBL2821456 | 0.81 | FOLH1 (0.50) | CA1CA2SMN1; SMN2TSHRMME | |
| SCHEMBL18124773 | 0.79 | ALDH1A1 (0.39) | ALDH1A1MGAMGAASIMGAM2 | |
| SCHEMBL685012 | 0.79 | ALDH1A1 (0.39) | ALDH1A1MGAMGAASIMGAM2 | |
| SCHEMBL10843170 | 0.79 | ALDH1A1 (0.44) | ALDH1A1MGAMGAASIMGAM2 | |
| SCHEMBL17305959 | 0.79 | ALDH1A1 (0.39) | ALDH1A1MGAMGAASIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297135-B1 | PROCESS FOR THE PREPARATION OF AN OREXIN RECEPTOR ANTAGONIST | MERCK SHARP & DOHME (US) | 2015-06-17 | — | — | EP | disclosed |
| CN-102123999-B | Process for the preparation of an orexin receptor antagonist | MERCK & CO INC | 2014-06-18 | — | — | CN | disclosed |
| US-8674093-B2 | Process for the preparation of an orexin receptor antagonist | MERCK CANADA INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-8674093-B2 | Process for the preparation of an orexin receptor antagonist | MERCK CANADA INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-8674093-B2 | Process for the preparation of an orexin receptor antagonist | MERCK CANADA INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-8569311-B2 | Pyridyl piperidine orexin receptor antagonists | Merch Sharp & Dohme Corp. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569311-B2 | Pyridyl piperidine orexin receptor antagonists | Merch Sharp & Dohme Corp. (US) | 2013-10-29 | — | — | US | disclosed |
| CN-101679366-B | Pyridyl piperidine orexin receptor antagonists | MERCK & CO INC | 2013-08-07 | — | — | CN | disclosed |
| US-20120295921-A1 | PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2012-11-22 | — | — | US | disclosed |
| US-20120295921-A1 | PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2012-11-22 | — | — | US | disclosed |
| US-20110165632-A1 | Process for the Preparation of an Orexin Receptor Antagonist | MERCK SHARP & DOHME LLC | 2011-07-07 | — | — | US | disclosed |
| US-20110165632-A1 | Process for the Preparation of an Orexin Receptor Antagonist | MERCK SHARP & DOHME LLC | 2011-07-07 | — | — | US | disclosed |
| US-20110165632-A1 | Process for the Preparation of an Orexin Receptor Antagonist | MERCK SHARP & DOHME LLC | 2011-07-07 | — | — | US | disclosed |
| US-20100168134-A1 | PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-07-01 | — | — | US | disclosed |
| US-20100168134-A1 | PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-07-01 | — | — | US | disclosed |
| CN-101679366-A | pyridyl piperidine orexin receptor antagonists | MERCK & CO INC | 2010-03-24 | — | — | CN | disclosed |
| WO-2009143033-A1 | PROCESS FOR THE PREPARATION OF AN OREXIN RECEPTOR ANTAGONIST | MERCK & CO., INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2008147518-A1 | PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| US-4577023-A | Diazabicyclo (2,2,2) octadiones | STAMICARBON B.V. (NL) | 1986-03-18 | — | — | US | disclosed |
| EP-0080245-A1 | Diazabicyclo(2,2,2)octadiones and process for their preparation | STAMICARBON B.V. (NL) | 1983-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110165632-A1 | Process for the Preparation of an Orexin Receptor Antagonist | HCRTR2, HCRTR1, OXTR | ALDH1A1 3272/4885MGAM 4521/4885GAA 1535/4885 |
| US-20120295921-A1 | PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | ALDH1A1 2437/4885MGAM 4867/4885GAA 2452/4885 |
| US-20100168134-A1 | PYRIDYL PIPERIDINE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | ALDH1A1 1366/4885MGAM 4869/4885GAA 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.